LBT Innovations Bags Up to AU$4.1 Million Contract with AstraZeneca; Shares Climb 33%
LBT Innovations (ASX:LBT) signed an agreement to sell five Automated Plate Assessment System (APAS) Independence instruments to AstraZeneca and provide maintenance and support services over seven years in a deal valued at AU$3.4 million to AU$4.1 million, according to a Wednesday filing with the Australian bourse.
The APAS instruments use artificial intelligence and machine learning software to automate the imaging, analysis, and interpretation of microbiology culture plates. They will be installed within the next six months, with a potential for additional orders, the filing said.
The medical technology company's shares climbed over 33% in recent trade.
Price (AUD): $0.02, Change: $+0.01, Percent Change: +33.33%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.